Alice Pomponio is Managing Director of BrightEdge, the American Cancer Society’s philanthropic venture impact fund. Alice brings more than 25 years of experience in life sciences and public policy coupled with her passion for the American Cancer Society’s lifesaving mission as a patient advocate and volunteer leader. She is an expert in rare disease and precision oncology, disruptive technology adoption, and companion diagnostic/therapeutic co-development strategies with an eye toward value-based care. Prior to ACS BrightEdge she was an advisor at Red Sky Partners LLC and the founder and managing director of Accendo. At Red Sky Partners, Alice advised high-growth life sciences and health tech companies on go-to-market and product value strategies. In 2018, she founded Accendo to accelerate entrepreneurial consumer-facing approaches to patient access and affordability of quality care. She previously held strategy and operational leadership roles at Radius Health, AstraZeneca, and Sanofi Genzyme, where she launched multiple US and global specialty products and championed orphan drug and health equity initiatives across the globe. Her public sector experience spans innovation, trade, and healthcare policy through roles in the UK Government and US Office of Management and Budget.
Alice holds a Master of Public Policy from Harvard University and a Bachelor of Science in Biology from MIT. She serves on the boards of Massachusetts Biotechnology Council, MassEcon, and PhagePro Inc. Additionally, she teaches entrepreneurship as a faculty member of Harvard-MIT HST Sloan Healthcare Ventures and MIT Catalyst where she focuses on patient-centric impact innovation.